Login / Signup

The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial.

Arnaud PagèsStéphanie FoulonZhaomin ZouLudovic LacroixFrançois LemareThierry de BaèreChristophe MassardJean-Charles SoriaJulia Bonastre
Published in: Genetics in medicine : official journal of the American College of Medical Genetics (2016)
This prospective cost analysis showed that molecular diagnosis accounts for only 6% of the cost of molecular-guided therapy per patient. The costs of drugs and hospitalizations are the main cost drivers.Genet Med advance online publication 01 December 2016.
Keyphrases
  • clinical trial
  • stem cells
  • healthcare
  • social media
  • phase iii
  • mesenchymal stem cells
  • open label
  • smoking cessation